Blood & Cancer

Oncologists are now weighing the benefits of treating cancer patients against the risk of exposing them to SARS-CoV-2. David Kerr, MD, DSc, of University of Oxford (England) talks with podcast host David H. Henry, MD, of Pennsylvania Hospital in Philadelphia, about how to treat colorectal cancer patients in the COVID-19 era. Dr. Kerr cowrote an article on MDedge Hematology/Oncology that outlined recommendations for treating colorectal cancer patients during the pandemic. In this episode, Dr. Henry and Dr. Kerr review those recommendations and compare notes on U.K. and U.S. practices. Disclosures: Dr. Henry reported having no financial disclosures relevant to this episode. Dr. Kerr has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd Ilana Yurkiewicz on Twitter:@ila